Literature DB >> 28108386

Trajectory of Improvement in Children and Adolescents With Chronic Migraine: Results From the Cognitive-Behavioral Therapy and Amitriptyline Trial.

John W Kroner1, James Peugh2, Susmita M Kashikar-Zuck2, Susan L LeCates3, Janelle R Allen4, Shalonda K Slater5, Marium Zafar1, Marielle A Kabbouche6, Hope L O'Brien6, Chad E Shenk2, Ashley M Kroon Van Diest1, Andrew D Hershey6, Scott W Powers7.   

Abstract

We compared headache frequency trajectories between clinical trial participants who received cognitive-behavioral therapy (CBT) and amitriptyline (CBT+A) or headache education (HE) and amitriptyline (HE+A) to determine if there was a differential time course of treatment response between the groups. One hundred thirty-five patients (age 10-17 years) diagnosed with chronic migraine participated, attending 8 one-hour one-on-one CBT or HE sessions with a trained psychologist for 8 weekly sessions, 2 sessions at weeks 12 and 16, and a post-treatment visit at week 20. Participants kept daily headache diaries and completed take-home assignments between visits. Data from daily headache diaries are presented for each day and according to 28-day periods. Trajectories of improvement indicate initial decrease in headache days began during the first month of treatment, for both groups, and continued to decrease throughout treatment. The CBT+A group had greater daily improvement than the HE+A group. A significantly greater proportion of the CBT+A group had a ≥50% reduction in headache days each month, and a significantly greater proportion of the CBT+A group had ≤4 headache days per month in months 3 through 5. Results indicate the trajectory of decrease in headache days is significantly better for patients receiving CBT+A versus HE+A. PERSPECTIVE: This article presents daily information about headache frequency over a 20-week clinical trial. Youth with chronic migraine who received CBT+A improved faster than those in the control group. Findings provide clinicians with evidence-based expectations for treatment response over time and ways of monitoring treatment success. TRIAL REGISTRATION: clinicaltrials.gov identifier NCT00389038.
Copyright © 2017 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pain; clinical trial; headache; pediatrics; treatment

Mesh:

Substances:

Year:  2017        PMID: 28108386      PMCID: PMC5457327          DOI: 10.1016/j.jpain.2017.01.002

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  18 in total

1.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

2.  Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators.

Authors:  Peer Tfelt-Hansen; Julio Pascual; Nabih Ramadan; Carl Dahlöf; Domenico D'Amico; Hans-Christopher Diener; Jakob Møller Hansen; Michel Lanteri-Minet; Elisabeth Loder; Douglas McCrory; Sandra Plancade; Todd Schwedt
Journal:  Cephalalgia       Date:  2012-01       Impact factor: 6.292

Review 3.  Methodological issues in clinical trials of drug and behavior therapies.

Authors:  Kenneth A Holroyd; Scott W Powers; Frank Andrasik
Journal:  Headache       Date:  2005-05       Impact factor: 5.887

4.  Methodological considerations in research with special populations: children and adolescents.

Authors:  Frank Andrasik; Scott W Powers; Patrick J McGrath
Journal:  Headache       Date:  2005-05       Impact factor: 5.887

5.  Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trial.

Authors:  Susmita Kashikar-Zuck; Tracy V Ting; Lesley M Arnold; Judy Bean; Scott W Powers; T Brent Graham; Murray H Passo; Kenneth N Schikler; Philip J Hashkes; Steven Spalding; Anne M Lynch-Jordan; Gerard Banez; Margaret M Richards; Daniel J Lovell
Journal:  Arthritis Rheum       Date:  2012-01

6.  Guidelines for trials of behavioral treatments for recurrent headache, first edition: American Headache Society Behavioral Clinical Trials Workgroup.

Authors:  Donald B Penzien; Frank Andrasik; Brian M Freidenberg; Timothy T Houle; Alvin E Lake; Gay L Lipchik; Kenneth A Holroyd; Richard B Lipton; Douglas C McCrory; Justin M Nash; Robert A Nicholson; Scott W Powers; Jeanetta C Rains; David A Wittrock
Journal:  Headache       Date:  2005-05       Impact factor: 5.887

Review 7.  Psychological therapies for the management of chronic and recurrent pain in children and adolescents.

Authors:  Christopher Eccleston; Tonya M Palermo; Amanda C de C Williams; Amy Lewandowski; Stephen Morley; Emma Fisher; Emily Law
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

8.  Effectiveness of amitriptyline in the prophylactic management of childhood headaches.

Authors:  A D Hershey; S W Powers; A L Bentti; T J Degrauw
Journal:  Headache       Date:  2000 Jul-Aug       Impact factor: 5.887

9.  Cognitive Behavioral Therapy plus Amitriptyline for Children and Adolescents with Chronic Migraine Reduces Headache Days to ≤4 Per Month.

Authors:  John W Kroner; Andrew D Hershey; Susmita M Kashikar-Zuck; Susan L LeCates; Janelle R Allen; Shalonda K Slater; Marium Zafar; Marielle A Kabbouche; Hope L O'Brien; Chad E Shenk; Joseph R Rausch; Ashley M Kroon Van Diest; Scott W Powers
Journal:  Headache       Date:  2016-03-18       Impact factor: 5.887

Review 10.  Psychological therapies for the management of chronic and recurrent pain in children and adolescents.

Authors:  Christopher Eccleston; Tonya M Palermo; Amanda C de C Williams; Amy Lewandowski Holley; Stephen Morley; Emma Fisher; Emily Law
Journal:  Cochrane Database Syst Rev       Date:  2014-05-05
View more
  6 in total

Review 1.  Cognitive Behavioral Therapy for Pediatric Headache and Migraine: Why to Prescribe and What New Research Is Critical for Advancing Integrated Biobehavioral Care.

Authors:  Ashley M Kroon Van Diest; Scott W Powers
Journal:  Headache       Date:  2018-11-16       Impact factor: 5.887

2.  Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.

Authors:  Christina L Szperka; Juliana VanderPluym; Serena L Orr; Christopher B Oakley; William Qubty; Irene Patniyot; Ana Marissa Lagman-Bartolome; Cynthia Morris; Jessica Gautreaux; M Cristina Victorio; Suzanne Hagler; Sona Narula; Meghan S Candee; Catalina Cleves-Bayon; Rashmi Rao; Robert H Fryer; Alma R Bicknese; Marcy Yonker; Andrew D Hershey; Scott W Powers; Peter J Goadsby; Amy A Gelfand
Journal:  Headache       Date:  2018-10-15       Impact factor: 5.887

3.  The Effects of Chronic Amitriptyline on Zebrafish Behavior and Monoamine Neurochemistry.

Authors:  Darya A Meshalkina; Elana V Kysil; Kristina A Antonova; Konstantin A Demin; Tatiana O Kolesnikova; Sergey L Khatsko; Raul R Gainetdinov; Polina A Alekseeva; Allan V Kalueff
Journal:  Neurochem Res       Date:  2018-05-08       Impact factor: 3.996

Review 4.  Non-Pharmacological Approaches to Headaches: Non-Invasive Neuromodulation, Nutraceuticals, and Behavioral Approaches.

Authors:  Licia Grazzi; Claudia Toppo; Domenico D'Amico; Matilde Leonardi; Paolo Martelletti; Alberto Raggi; Erika Guastafierro
Journal:  Int J Environ Res Public Health       Date:  2021-02-05       Impact factor: 3.390

Review 5.  From the New Diagnostic Criteria to COVID-19 Pandemic Passing Through the Placebo Effect. What Have We Learned in the Management of Pediatric Migrane Over the Past 5 Years?

Authors:  Laura Papetti; Samuela Tarantino; Fabiana Ursitti; Romina Moavero; Martina Checchi Proietti; Giorgia Sforza; Gabriele Monte; Michela Ada Noris Ferilli; Martina Balestri; Federico Vigevano; Massimiliano Valeriani
Journal:  Front Neurol       Date:  2022-07-13       Impact factor: 4.086

Review 6.  Management of Chronic Migraine in Children and Adolescents: Where are We in 2022?

Authors:  Robert C Gibler; Kaelynn E Knestrick; Brooke L Reidy; Daniel N Lax; Scott W Powers
Journal:  Pediatric Health Med Ther       Date:  2022-09-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.